{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:05:46Z","timestamp":1790856346538,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vedolizumab, an antibody blocking integrin \u03b14\u03b27, is a safe and effective therapy for Crohn\u2019s disease and ulcerative colitis. Blocking \u03b14\u03b27 from binding its cognate addressin MAdCAM-1 on intestinal blood vessel endothelial cells prevents T cells from migrating to the gut mucosa in animal models. However, data supporting this mechanism of action in humans is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional case-control study to evaluate the effect of vedolizumab on intestinal immune cell populations while avoiding the confounding effect of resolving inflammation on the cellularity of the colonic mucosa in treatment-responsive patients. Colon biopsies from 65 case subjects receiving vedolizumab were matched with biopsies from 65 control individuals, similar in disease type, medications, anatomic location, and inflammation. Biopsies were analyzed by flow cytometry and full messenger RNA transcriptome sequencing of sorted T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No difference was seen between vedolizumab recipients and control individuals in the quantity of any antigen-experienced T lymphocyte subset or in the quality of the transcriptome in any experienced T cell subset. Fewer na\u00efve colonic B and T cells were seen in vedolizumab recipients than control individuals, regardless of response. However, the most striking finding was a marked reduction in CD1c+ (BDCA1+) dendritic cells exclusively in vedolizumab-responsive patients. In blood, these dendritic cells ubiquitously express high levels of \u03b14\u03b27, which is rapidly downregulated upon vedolizumab exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinical effects of vedolizumab reveal integrin \u03b14\u03b27-dependent dendritic cell migration to the intestinal mucosa to be central to inflammatory bowel disease pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izad224","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:12:40Z","timestamp":1694167960000},"page":"704-717","source":"Crossref","is-referenced-by-count":20,"title":["Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells"],"prefix":"10.1093","volume":"30","author":[{"given":"Elisa K","family":"Boden","sequence":"first","affiliation":[{"name":"Center for Translational Research, Benaroya Research Institute , Seattle, WA , USA"},{"name":"Division of Gastroenterology, Oregon Health and Science University , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Kongala","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Benaroya Research Institute , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan C","family":"Hindmarch","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Benaroya Research Institute , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M","family":"Shows","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Benaroya Research Institute , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius G","family":"Juarez","sequence":"additional","affiliation":[{"name":"GI Drug Discovery, Takeda Pharmaceuticals , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-3660","authenticated-orcid":false,"given":"James D","family":"Lord","sequence":"additional","affiliation":[{"name":"Center for Translational Research, Benaroya Research Institute , Seattle, WA , USA"},{"name":"Division of Gastroenterology, Virginia Mason Medical Center , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"issue":"8","key":"2024050205521149300_CIT0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2024050205521149300_CIT0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2024050205521149300_CIT0003","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"6944","key":"2024050205521149300_CIT0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature01726","article-title":"Selective imprinting of gut-homing T cells by Peyer\u2019s patch dendritic cells","volume":"424","author":"Mora","year":"2003","journal-title":"Nature."},{"issue":"6","key":"2024050205521149300_CIT0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.20031244","article-title":"Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant","volume":"198","author":"Johansson-Lindbom","year":"2003","journal-title":"J Exp Med."},{"issue":"1","key":"2024050205521149300_CIT0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell."},{"issue":"1","key":"2024050205521149300_CIT0007","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol."},{"issue":"3","key":"2024050205521149300_CIT0008","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/gast.2002.31899","article-title":"Intravital observation of adhesion of lamina propria lymphocytes to microvessels of small intestine in mice","volume":"122","author":"Fujimori","year":"2002","journal-title":"Gastroenterology."},{"issue":"7","key":"2024050205521149300_CIT0009","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.152.7.3282","article-title":"Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo","volume":"152","author":"Hamann","year":"1994","journal-title":"J Immunol."},{"issue":"5","key":"2024050205521149300_CIT0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.158.5.2099","article-title":"Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells","volume":"158","author":"Picarella","year":"1997","journal-title":"J Immunol."},{"issue":"1","key":"2024050205521149300_CIT0011","first-page":"183","article-title":"Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1","volume":"295","author":"Kato","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"2024050205521149300_CIT0012","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-world lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol."},{"issue":"15","key":"2024050205521149300_CIT0013","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology."},{"issue":"9","key":"2024050205521149300_CIT0014","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease","volume":"63","author":"Boden","year":"2018","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2024050205521149300_CIT0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ecco-jcc\/jjaa178","article-title":"Dissecting common and unique effects of anti-alpha4beta7 and anti-tumor necrosis factor treatment in ulcerative colitis","volume":"15","author":"Veny","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"461","key":"2024050205521149300_CIT0016","doi-asserted-by":"crossref","first-page":"eaau4711","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Sci Transl Med."},{"key":"2024050205521149300_CIT0017","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases","volume":"9","author":"Rath","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"2024050205521149300_CIT0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2018","journal-title":"Gut."},{"issue":"3","key":"2024050205521149300_CIT0019","first-page":"614","article-title":"Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease","volume":"53","author":"Selby","year":"1983","journal-title":"Clin Exp Immunol."},{"issue":"8","key":"2024050205521149300_CIT0020","doi-asserted-by":"crossref","first-page":"e0136485","DOI":"10.1371\/journal.pone.0136485","article-title":"Human blood and mucosal regulatory T cells express activation markers and inhibitory receptors in inflammatory bowel disease","volume":"10","author":"Lord","year":"2015","journal-title":"PLoS One."},{"issue":"1","key":"2024050205521149300_CIT0021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/00365521.2013.853829","article-title":"Naive T cells correlate with mucosal healing in patients with inflammatory bowel disease","volume":"49","author":"Karlsson","year":"2014","journal-title":"Scand J Gastroenterol."},{"issue":"8","key":"2024050205521149300_CIT0022","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205521149300_CIT0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clim.2018.05.006","article-title":"Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype","volume":"193","author":"Lord","year":"2018","journal-title":"Clin Immunol."},{"issue":"3","key":"2024050205521149300_CIT0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41385-021-00467-7","article-title":"Human mucosal tissue-resident memory T cells in health and disease","volume":"15","author":"Lange","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"1","key":"2024050205521149300_CIT0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2249.2004.02578.x","article-title":"Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo","volume":"138","author":"Kelsen","year":"2004","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"2024050205521149300_CIT0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MIB.0000000000000242","article-title":"T-cell receptor sequencing reveals the clonal diversity and overlap of colonic effector and FOXP3+ T cells in ulcerative colitis","volume":"21","author":"Lord","year":"2015","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024050205521149300_CIT0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MIB.0000000000000221","article-title":"On naivety of T cells in inflammatory bowel disease: a review","volume":"21","author":"Smids","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205521149300_CIT0028","doi-asserted-by":"crossref","first-page":"559166","DOI":"10.3389\/fimmu.2020.559166","article-title":"Subsets of CD1c(+) DCs: dendritic cell versus monocyte lineage","volume":"11","author":"Heger","year":"2020","journal-title":"Front Immunol."},{"key":"2024050205521149300_CIT0029","doi-asserted-by":"crossref","first-page":"643240","DOI":"10.3389\/fimmu.2021.643240","article-title":"Tolerogenic immunotherapy: targeting DC surface receptors to induce antigen-specific tolerance","volume":"12","author":"Castenmiller","year":"2021","journal-title":"Front Immunol."},{"key":"2024050205521149300_CIT0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fimmu.2017.00971","article-title":"Human blood CD1c(+) dendritic cells promote Th1 and Th17 effector function in memory CD4(+) T cells","volume":"8","author":"Leal Rojas","year":"2017","journal-title":"Front Immunol."},{"issue":"9","key":"2024050205521149300_CIT0031","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.4049\/jimmunol.179.9.6255","article-title":"The role of dendritic cells in the development of acute dextran sulfate sodium colitis","volume":"179","author":"Berndt","year":"2007","journal-title":"J Immunol."},{"issue":"2","key":"2024050205521149300_CIT0032","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/mi.2015.64","article-title":"Intestinal CD103(+)CD11b(-) dendritic cells restrain colitis via IFN-gamma-induced anti-inflammatory response in epithelial cells","volume":"9","author":"Muzaki","year":"2016","journal-title":"Mucosal Immunol"},{"issue":"1","key":"2024050205521149300_CIT0033","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clim.2014.11.005","article-title":"Localization of dendritic cells in the gut epithelium requires MAdCAM-1","volume":"156","author":"Clahsen","year":"2015","journal-title":"Clin Immunol."},{"issue":"11","key":"2024050205521149300_CIT0034","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"2024050205521149300_CIT0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study","volume":"56","author":"Vande Casteele","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2024050205521149300_CIT0036","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ibd\/izab143","article-title":"Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn disease: Posthoc Analysis of the LOVE-CD Study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024050205521149300_CIT0037","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/imm.13320","article-title":"Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease","volume":"163","author":"Patel","year":"2021","journal-title":"Immunology."},{"issue":"2","key":"2024050205521149300_CIT0038","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology."},{"issue":"6","key":"2024050205521149300_CIT0039","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology."},{"issue":"1","key":"2024050205521149300_CIT0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology."},{"issue":"2","key":"2024050205521149300_CIT0041","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","article-title":"Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn\u2019s disease","volume":"19","author":"Biancheri","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2024050205521149300_CIT0042","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ibd\/izac151","article-title":"Transcriptional behavior of regulatory T cells predicts IBD patient responses to vedolizumab therapy","volume":"28","author":"Abreu","year":"2022","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad224\/54809645\/izad224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/5\/704\/57299376\/izad224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/5\/704\/57299376\/izad224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T01:54:39Z","timestamp":1714614879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/5\/704\/7317661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,14]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad224","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,10,14]]}}}